Feinberg
Northwestern Medicine | Northwestern University | Faculty Profiles

News Center

  • Categories
    • Campus News
    • Disease Discoveries
    • Clinical Breakthroughs
    • Education News
    • Scientific Advances
  • Press Release
  • Media Coverage
  • Podcasts
  • Editor’s Picks
    • COVID-19
    • Cardiology
    • Cancer
    • Neurology and Neuroscience
    • Aging and Longevity
    • Artificial Intelligence in Medicine
  • News Archives
  • About Us
    • Media Contact
    • Share Your News
    • News Feeds
    • Social Media
    • Contact Us
Menu
  • Categories
    • Campus News
    • Disease Discoveries
    • Clinical Breakthroughs
    • Education News
    • Scientific Advances
  • Press Release
  • Media Coverage
  • Podcasts
  • Editor’s Picks
    • COVID-19
    • Cardiology
    • Cancer
    • Neurology and Neuroscience
    • Aging and Longevity
    • Artificial Intelligence in Medicine
  • News Archives
  • About Us
    • Media Contact
    • Share Your News
    • News Feeds
    • Social Media
    • Contact Us
Home » Northwestern Study to Test Parkinson’s Drug
Clinical Breakthroughs

Northwestern Study to Test Parkinson’s Drug

By Marla PaulApr 2, 2014
Share
Facebook Twitter Email

Tanya Simuni, MD, medical director of Northwestern University’s Parkinson’s Disease and Movement Disorders Center, was awarded a grant from the National Institutes of Health (NIH) to conduct a $16 million phase III study of the safety and efficacy of the drug isradipine as a potential neuroprotective agent in Parkinson’s disease.

This is the only phase III Parkinson’s neuroprotective study currently funded by the National Institute of Neurological Disorders and Stroke at NIH. The research is being conducted by Northwestern University Feinberg School of Medicine in partnership with the University of Rochester Medical Center. The study will be carried out at 56 Parkinson Study Group centers in North America over five years.

“If this drug proves to be safe and effective, it will change the way we treat Parkinson’s disease,” said Simuni, the principal investigator of the study. “The major advantage is isradipine is already widely available and inexpensive and will allow for rapid translation of our research into clinical practice. Although we now have very effective symptomatic treatments to manage Parkinson’s, the development of a disease-modifying intervention remains the Holy Grail.”

Simuni is the Arthur C. Nielsen, Jr. Research Professor in Parkinson’s Disease and Movement Disorders at Feinberg and a neurologist at Northwestern Memorial Hospital.

Parkinson’s is the second most common neurodegenerative disease. Prominent traits include tremor, stiffness of the limbs and trunk, slowness of movement and impaired balance and coordination. While there are pharmaceutical and alternative therapies available to manage the disease, there are currently no cures or treatments that definitively slow its progression. Researchers are looking for treatments to delay disease progression. If isradipine proves effective, the drug could revolutionize the treatment of Parkinson’s.

Isradipine has been approved by the Food and Drug Administration as a calcium-channel blocker to treat hypertension (high blood pressure). Isradipine blocks excessive influx of calcium into the brain cells responsible for development of Parkinson’s.

Northwestern researchers, led by D. James Surmeier, PhD, the Nathan Smith Davis Professor of Physiology and director of the Udall Center of Excellence for Parkinson’s Disease Research, discovered that calcium entry through a membrane protein blocked by isradipine could be killing dopamine-producing neurons and causing Parkinson’s.

Dopamine is a critical chemical messenger in the brain that directs a person’s ability to move. It is hypothesized that isradipine will slow the progression of the disease by protecting dopamine-producing neurons from calcium toxicity over an extended period of time.

Academic colleagues at Feinberg, including Surmeier, will collaborate with Simuni on this study. The physiology department headed by Surmeier is one of the nation’s premier groups studying the physiology of movement disorders.

To participate or learn more about this study, contact the research team at Northwestern’s Parkinson’s Disease and Movement Disorders Center at (312) 503-0755 or by emailing pdclinicaltrials@northwestern.edu.

The research is funded by grants 1 U01 NS080818-01A and 1 U01 NS080840-01A1 from the National Institute of Neurological Disorders and Stroke at NIH.

The study also is supported by Carematix and Verizon.

Neurology and Neuroscience Physiology Research
Share. Facebook Twitter Email

Related Posts

Humans are Not Just Big Mice: Identifying Science’s Muscle-Scaling Problem

Mar 20, 2023

Predicting Risk of Blood Clots in Brain Tumors

Mar 16, 2023

Understanding How Exercise Induces Systemic Metabolic Benefits

Mar 15, 2023

Comments are closed.

Latest News

Humans are Not Just Big Mice: Identifying Science’s Muscle-Scaling Problem

Mar 20, 2023

AOA Honors New Members

Mar 20, 2023

Celebrating Feinberg’s 2023 Match Day

Mar 17, 2023

Predicting Risk of Blood Clots in Brain Tumors

Mar 16, 2023

Understanding How Exercise Induces Systemic Metabolic Benefits

Mar 15, 2023
  • News Center Home
  • Categories
  • Press Release
  • Media Coverage
  • Editor’s Picks
  • News Archives
  • About Us
Flickr Photos
_5NM1245
230204_SERIO_MANDELL_Feinberg_Formal_0928
_5NM1715
_5NM0526
_5NM1026 (1)
_5NM1906
_5NM2173
230204_SERIO_MANDELL_Feinberg_Formal_0896
230204_SERIO_MANDELL_Feinberg_Formal_1113
230204_SERIO_MANDELL_Feinberg_Formal_1868
230204_SERIO_MANDELL_Feinberg_Formal_1237
230204_SERIO_MANDELL_Feinberg_Formal_1172

Northwestern University logo

Northwestern University Feinberg School of Medicine

RSS Facebook Twitter LinkedIn Flickr YouTube Instagram
Copyright © 2023 Northwestern University
  • Contact Northwestern University
  • Disclaimer
  • Campus Emergency Information
  • Policy Statements

Type above and press Enter to search. Press Esc to cancel.